Immunomodulating drugs

The Anti-Bromodeoxyuridine Antibody is supplied in the same formulation as the monoclonal antibody to BrdU in the kit. The antibody/nuclease mixture is compatible with detection systems that incorporate fluorescently labeled antibodies and

5&#8242-Bromo-2-deoxyuridine (BrdU) is a carcinogen that may be absorbed by skin or inhalation. BrdU solutions are sensitive to light.

5&#8242-Bromo-2-deoxyuridine (BrdU) is a carcinogen that may be absorbed by skin or inhalation. BrdU solutions are sensitive to light.

5&#8242-Bromo-2-deoxyuridine (BrdU) is a carcinogen that may be absorbed by skin or inhalation. BrdU solutions are sensitive to light.

Immunogen BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by

Immunogen BRF1, RNA polymerase III transcription initiation factor subunit Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the

The gene BRF2 (b-related factor 2) is mapped to human chromosome 8p11.23.

Immunogen brain protein I3 recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the

BRI3BP (BRI3 binding protein) is an oncogene, which is a HCCR (human cervical cancer)-interacting protein, and is also called HCCRBP-1. This protein is composed of 166 amino acids, and has a molecular weight of 19kDa.

BRICD5 (BRICHOS domain-containing protein 5) belongs to the BRICHOS family and contains a BRICHOS domain. Immunogen Hypothetical protein LOC283870 recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by

Immunogen BRICHOS domain containing 5 Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the

Immunogen deleted in bladder cancer 1 recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are